You are here:
A Public-Private Consortium Advances Cardiac Safety Evaluation: Achievements of the HESI Cardiac Safety Technical Committee
Pierson, J., B. Berridge, M. Brooks, K. Dreher, J. Koerner, A. Schultze, R. Sarazan, J. Valentin, H. Vargas, AND S. Pettit. A Public-Private Consortium Advances Cardiac Safety Evaluation: Achievements of the HESI Cardiac Safety Technical Committee. JOURNAL OF PHARMACOLOGICAL & TOXICOLOGICAL METHODS. Elsevier Science Ltd, New York, NY, 68(1):7-12, (2013).
The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues have been and continue to be a major cause of attrition and withdrawal due to Adverse Drug Reactions (ADRs) in pharmaceutical drug development. The HESI Technical Committee on Cardiac Safety, an international consortium of academic, government, and industry scientists, provides a unique opportunity to share resources and expertise to improve cardiovascular safety evaluation for new drugs and chemicals. This article describes the evolution of the HESI Cardiac Safety Technical Committee from 2000-2013 and the positive impacts resulting from this collaboration.
Identifies and highlights commonality for health risk assessment needs between safe drugs AND chemical safety risk assessment as well as the use of stem cell technologies to assess both drug and chemical safety for regulatory decisions
URLs/Downloads:PIERSON ET AL J PHARMACOL TOXICOL METH 2013 ABSTRACT AND CITATION.PDF (PDF,NA pp, 15.753 KB, about PDF)
Record Details:Record Type: DOCUMENT (JOURNAL/PEER REVIEWED JOURNAL)
Organization:U.S. ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF RESEARCH AND DEVELOPMENT
NATIONAL HEALTH AND ENVIRONMENTAL EFFECTS RESEARCH LAB
ENVIRONMENTAL PUBLIC HEALTH DIVISION
CARDIOPULMONARY AND IMMUNOTOXICOLOGY BRANCH